Oncotarget

Reviews:

Long non-coding RNAs in osteosarcoma

Ruiling Chen, Gangyang Wang, Ying Zheng, Yingqi Hua and Zhengdong Cai _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:20462-20475. https://doi.org/10.18632/oncotarget.14726

Metrics: PDF 2285 views  |   HTML 2186 views  |   ?  


Abstract

Ruiling Chen1,*, Gangyang Wang1,*, Ying Zheng1, Yingqi Hua1 and Zhengdong Cai1

1 Department of Orthopaedics, Shanghai Bone Tumor Institute, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

* These authors have contributed equally to this work

Correspondence to:

Zhengdong Cai, email:

Yingqi Hua, email:

Keywords: osteosarcoma; lncRNA; pathogenesis; biomarkers; therapeutic targets

Received: October 12, 2016 Accepted: January 09, 2017 Published: January 18, 2017

Abstract

Long non-coding RNAs (lncRNAs) with more than 200 nuleotides, have been explored to participate in various cancer types including osteosarcoma (OS), which is the most common kind of primary bone tumors with high morbidity in infants and adolescents. These oncogenic or tumor suppressive lncRNAs regulate OS pathogenesis, such as cell growth, proliferation, invasion, migration, metastasis and cell apoptosis, serve as independent prognostic biomarkers or play a significant role in multidrug resistance (MDR) in OS cells. In this review, we attempt to dissect the participation of lncRNAs in pathogenesis of OS and their potential clinical values, and also provide an outlook for viable biomarkers and therapeutic targets in OS.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14726